Olink Holding AB (OLK)
23.94
-0.01
(-0.04%)
USD |
NASDAQ |
May 17, 16:00
23.94
0.00 (0.00%)
After-Hours: 20:00
Olink Revenue (Quarterly): 28.75M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 28.75M |
| December 31, 2023 | 68.55M |
| September 30, 2023 | 44.15M |
| June 30, 2023 | 29.44M |
| March 31, 2023 | 27.46M |
| December 31, 2022 | 57.88M |
| September 30, 2022 | 31.77M |
| June 30, 2022 | 27.51M |
| March 31, 2022 | 22.68M |
| Date | Value |
|---|---|
| December 31, 2021 | 43.68M |
| September 30, 2021 | 19.97M |
| June 30, 2021 | 17.69M |
| March 31, 2021 | 13.63M |
| December 31, 2020 | 27.19M |
| September 30, 2020 | 11.00M |
| June 30, 2020 | 7.884M |
| March 31, 2020 | 7.998M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
7.884M
Minimum
Jun 2020
68.55M
Maximum
Dec 2023
28.66M
Average
27.46M
Median
Mar 2023
Revenue (Quarterly) Benchmarks
| Thermo Fisher Scientific Inc | 10.34B |
| Abliva AB | 0.0129M |
| Karolinska Development AB | 0.0454M |
| Calliditas Therapeutics AB | 42.53M |
| Oncopeptides AB | 0.26M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -16.06M |
| Total Expenses (Quarterly) | 53.69M |
| EPS Diluted (Quarterly) | -0.13 |
| Enterprise Value | 2.869B |
| Gross Profit Margin (Quarterly) | 60.68% |
| Profit Margin (Quarterly) | -55.87% |
| Earnings Yield | -1.13% |
| Normalized Earnings Yield | -1.351 |